• Jan O Jansen, Jemma Hudson, Claire Cochran, Graeme MacLennan, Robbie Lendrum, Sam Sadek, Katie Gillies, Seonaidh Cotton, Charlotte Kennedy, Dwayne Boyers, Gillian Ferry, Louisa Lawrie, Mintu Nath, Samantha Wileman, Mark Forrest, Karim Brohi, Tim Harris, Fiona Lecky, Chris Moran, Jonathan J Morrison, John Norrie, Alan Paterson, Nigel Tai, Nick Welch, Marion K Campbell, UK-REBOA Study Group, Chris Aylwin, Duncan Bew, Adam Brooks, James Chinery, Tom Cowlam, Dan Frith, Arun George, Anthony Hudson, Phillip Johnstone, Ansar Mahmood, Alex Novak, Matt O'Meara, Stuart Reid, Abdo Sattout, Chris Smith, Tim Stansfield, and Julian Thompson.
• Health Services Research Unit, University of Aberdeen, Aberdeen, Scotland.
• JAMA. 2023 Nov 21; 330 (19): 186218711862-1871.

ImportanceBleeding is the most common cause of preventable death after trauma.ObjectiveTo determine the effectiveness of resuscitative endovascular balloon occlusion of the aorta (REBOA) when used in the emergency department along with standard care vs standard care alone on mortality in trauma patients with exsanguinating hemorrhage.Design, Setting, And ParticipantsPragmatic, bayesian, randomized clinical trial conducted at 16 major trauma centers in the UK. Patients aged 16 years or older with exsanguinating hemorrhage were enrolled between October 2017 and March 2022 and followed up for 90 days.InterventionPatients were randomly assigned (1:1 allocation) to a strategy that included REBOA and standard care (n = 46) or standard care alone (n = 44).Main Outcomes And MeasuresThe primary outcome was all-cause mortality at 90 days. Ten secondary outcomes included mortality at 6 months, while in the hospital, and within 24 hours, 6 hours, or 3 hours; the need for definitive hemorrhage control procedures; time to commencement of definitive hemorrhage control procedures; complications; length of stay; blood product use; and cause of death.ResultsOf the 90 patients (median age, 41 years [IQR, 31-59 years]; 62 [69%] were male; and the median Injury Severity Score was 41 [IQR, 29-50]) randomized, 89 were included in the primary outcome analysis because 1 patient in the standard care alone group declined to provide consent for continued participation and data collection 4 days after enrollment. At 90 days, 25 of 46 patients (54%) had experienced all-cause mortality in the REBOA and standard care group vs 18 of 43 patients (42%) in the standard care alone group (odds ratio [OR], 1.58 [95% credible interval, 0.72-3.52]; posterior probability of an OR >1 [indicating increased odds of death with REBOA], 86.9%). Among the 10 secondary outcomes, the ORs for mortality and the posterior probabilities of an OR greater than 1 for 6-month, in-hospital, and 24-, 6-, or 3-hour mortality were all increased in the REBOA and standard care group, and the ORs were increased with earlier mortality end points. There were more deaths due to bleeding in the REBOA and standard care group (8 of 25 patients [32%]) than in standard care alone group (3 of 18 patients [17%]), and most occurred within 24 hours.Conclusions And RelevanceIn trauma patients with exsanguinating hemorrhage, a strategy of REBOA and standard care in the emergency department does not reduce, and may increase, mortality compared with standard care alone.Trial Registrationisrctn.org Identifier: ISRCTN16184981.

31 keywords...

hide…